Biotron Ltd has released a press release.
BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Positive outcomes in BIT225 phase 2 clinical trial in hiv
- Response to ASX Price Query
- Completion of phase 2 covid clinical trial
- Second Site Approved for Phase 2 Covid-19 Trial
- Commencement Phase 2 Covid-19 Clinical Trial
Later from Biotron
- BIT225-012 phase 2 covid-19 clinical trial
- $1.8M R&D Rebate Received
- Agreement with C14 Consulting Group
- Updated Appendix 4C
- Renounceable Rights Issue
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron